588.34
price down icon1.43%   -8.51
after-market After Hours: 586.33 -2.01 -0.34%
loading
Regeneron Pharmaceuticals Inc stock is traded at $588.34, with a volume of 653.98K. It is down -1.43% in the last 24 hours and up +0.08% over the past month. Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$596.85
Open:
$586.85
24h Volume:
653.98K
Relative Volume:
0.61
Market Cap:
$62.45B
Revenue:
$14.09B
Net Income/Loss:
$4.50B
P/E Ratio:
14.98
EPS:
39.28
Net Cash Flow:
$2.96B
1W Performance:
-1.01%
1M Performance:
+0.08%
6M Performance:
-20.28%
1Y Performance:
-40.00%
1-Day Range:
Value
$582.37
$591.64
1-Week Range:
Value
$582.37
$617.52
52-Week Range:
Value
$520.50
$1,211.20

Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile

Name
Name
Regeneron Pharmaceuticals Inc
Name
Phone
(914) 847-7000
Name
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Name
Employee
15,158
Name
Twitter
@regeneron
Name
Next Earnings Date
2025-02-04
Name
Latest SEC Filings
Name
REGN's Discussions on Twitter

Compare REGN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
588.34 63.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ONC
Beigene Ltd Adr
241.43 24.41B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
436.00 111.55B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.335 42.47M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
75.06 5.92B 0 -153.72M -103.81M -2.00

Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades

Date Action Analyst Rating Change
May-14-25 Upgrade Citigroup Neutral → Buy
Apr-22-25 Resumed Cantor Fitzgerald Overweight
Feb-05-25 Upgrade Leerink Partners Market Perform → Outperform
Jan-16-25 Downgrade UBS Buy → Neutral
Dec-10-24 Resumed BofA Securities Underperform
Nov-15-24 Initiated Wolfe Research Outperform
Nov-14-24 Initiated Citigroup Neutral
Sep-24-24 Downgrade Leerink Partners Outperform → Market Perform
Mar-12-24 Initiated Bernstein Outperform
Jan-12-24 Upgrade RBC Capital Mkts Sector Perform → Outperform
Nov-09-23 Initiated Deutsche Bank Hold
Nov-03-23 Upgrade Raymond James Mkt Perform → Outperform
Aug-21-23 Upgrade Canaccord Genuity Hold → Buy
Aug-21-23 Reiterated Oppenheimer Perform
Jun-28-23 Downgrade Canaccord Genuity Buy → Hold
Mar-27-23 Upgrade SVB Securities Market Perform → Outperform
Mar-24-23 Upgrade Jefferies Hold → Buy
Mar-23-23 Upgrade Raymond James Underperform → Mkt Perform
Jan-30-23 Upgrade Cowen Market Perform → Outperform
Jan-20-23 Upgrade JP Morgan Neutral → Overweight
Oct-26-22 Downgrade Raymond James Mkt Perform → Underperform
Oct-17-22 Downgrade Evercore ISI Outperform → In-line
Sep-09-22 Upgrade Jefferies Underperform → Hold
Sep-09-22 Upgrade Morgan Stanley Equal-Weight → Overweight
Jul-25-22 Downgrade SVB Leerink Outperform → Mkt Perform
Jul-13-22 Initiated Cantor Fitzgerald Neutral
Jun-06-22 Initiated Jefferies Underperform
May-23-22 Initiated SVB Leerink Outperform
Jan-05-22 Downgrade BofA Securities Neutral → Underperform
Jan-03-22 Upgrade Bernstein Mkt Perform → Outperform
Dec-15-21 Downgrade Bernstein Outperform → Mkt Perform
Dec-09-21 Resumed Wells Fargo Overweight
Dec-07-21 Resumed Cowen Market Perform
Dec-06-21 Initiated Goldman Buy
Nov-19-21 Resumed BMO Capital Markets Outperform
Nov-05-21 Downgrade The Benchmark Company Buy → Hold
Jun-29-21 Initiated H.C. Wainwright Buy
Jan-25-21 Upgrade BMO Capital Markets Market Perform → Outperform
Jan-13-21 Upgrade The Benchmark Company Hold → Buy
Jan-08-21 Upgrade Citigroup Neutral → Buy
Oct-05-20 Upgrade Cantor Fitzgerald Neutral → Overweight
Aug-20-20 Downgrade The Benchmark Company Buy → Hold
Jul-09-20 Upgrade SunTrust Hold → Buy
May-26-20 Upgrade Wells Fargo Equal Weight → Overweight
Apr-28-20 Downgrade Citigroup Buy → Neutral
Apr-17-20 Upgrade The Benchmark Company Hold → Buy
Apr-08-20 Initiated The Benchmark Company Hold
Mar-31-20 Initiated Wolfe Research Peer Perform
Feb-27-20 Initiated Barclays Overweight
Feb-26-20 Upgrade Canaccord Genuity Hold → Buy
Feb-26-20 Downgrade Robert W. Baird Outperform → Neutral
Feb-25-20 Upgrade Jefferies Hold → Buy
Feb-11-20 Upgrade Argus Hold → Buy
Dec-24-19 Initiated Raymond James Mkt Perform
Dec-16-19 Downgrade Evercore ISI Outperform → In-line
Dec-13-19 Upgrade Credit Suisse Neutral → Outperform
Nov-12-19 Initiated SunTrust Hold
Nov-07-19 Upgrade Citigroup Neutral → Buy
Oct-17-19 Resumed BofA/Merrill Neutral
Sep-23-19 Upgrade Guggenheim Neutral → Buy
View All

Regeneron Pharmaceuticals Inc Stock (REGN) Latest News

pulisher
03:30 AM

Regeneron Initial Data on Multiple Myeloma Drug Encouraging - Zacks Investment Research

03:30 AM
pulisher
01:32 AM

Regeneron Pharmaceuticals (NasdaqGS:REGN) Reports Promising Results In LINKER-MM2 Trial For Linvoseltamab - simplywall.st

01:32 AM
pulisher
11:06 AM

Tidal Investments LLC Grows Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

11:06 AM
pulisher
09:12 AM

USS Investment Management Ltd Sells 1,440 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

09:12 AM
pulisher
09:10 AM

Bayer wins EU recommendation for label expansion of Regeneron-partnered Eylea - Seeking Alpha

09:10 AM
pulisher
08:02 AM

Vident Advisory LLC Grows Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

08:02 AM
pulisher
06:54 AM

Williams Jones Wealth Management LLC. Sells 715 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

06:54 AM
pulisher
06:46 AM

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Lowered by Jacobs Levy Equity Management Inc. - MarketBeat

06:46 AM
pulisher
05:34 AM

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Royal Bank of Canada - MarketBeat

05:34 AM
pulisher
04:49 AM

8MM Bronchiectasis Market Opportunity Assessment and Forecasts, 2033 - GlobeNewswire Inc.

04:49 AM
pulisher
03:21 AM

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Quantinno Capital Management LP - MarketBeat

03:21 AM
pulisher
02:45 AM

Janus Henderson Group PLC Sells 84,661 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

02:45 AM
pulisher
May 22, 2025

Strive Asset Management LLC Invests $419,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

May 22, 2025
pulisher
May 22, 2025

Regeneron to acquire bankrupt genetic testing firm 23andMe for US$256 million - Proactive Investors

May 22, 2025
pulisher
May 22, 2025

Litigators of the Week: A $406.8M Win for Regeneron in Antitrust Trial Showdown With Cholesterol Drug Rival Amgen - Law.com

May 22, 2025
pulisher
May 22, 2025

Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years - Benzinga

May 22, 2025
pulisher
May 22, 2025

Regeneron Pharmaceuticals Reveals Trial Data of Drug Combination to Treat Multiple Myeloma - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stake Lifted by Scientech Research LLC - MarketBeat

May 22, 2025
pulisher
May 22, 2025

Regeneron (REGN) Reports Promising Trial Results for Linvoseltamab in Multiple Myeloma | REGN Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Breakthrough: Regeneron's Multiple Myeloma Drug Shows 90% Response Rate in New Combination Therapy Trial - Stock Titan

May 22, 2025
pulisher
May 22, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Made A “Very Smart Deal,” Says Jim Cramer - Insider Monkey

May 22, 2025
pulisher
May 22, 2025

Bayer wins China approval for high-dose Eylea (REGN:NASDAQ) - Seeking Alpha

May 22, 2025
pulisher
May 22, 2025

AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition - GlobeNewswire

May 22, 2025
pulisher
May 22, 2025

AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition - Benzinga

May 22, 2025
pulisher
May 22, 2025

Worldquant Millennium Advisors LLC Has $75.02 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

May 22, 2025
pulisher
May 22, 2025

Regeneron Enters into Agreement to Acquire Consumer Genetics Business - thehudsonindependent.com

May 22, 2025
pulisher
May 22, 2025

Voloridge Investment Management LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

May 22, 2025
pulisher
May 22, 2025

Woodline Partners LP Buys 3,862 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

May 22, 2025
pulisher
May 22, 2025

Twinbeech Capital LP Has $17.91 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

May 22, 2025
pulisher
May 22, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $890.60 Average Price Target from Analysts - MarketBeat

May 22, 2025
pulisher
May 22, 2025

Tema Etfs LLC Invests $4.17 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

May 22, 2025
pulisher
May 22, 2025

Pathstone Holdings LLC Sells 1,254 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

May 22, 2025
pulisher
May 21, 2025

Regeneron to buy 23andMe for $256M in court-supervised sale - MSN

May 21, 2025
pulisher
May 21, 2025

1,064 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Acquired by Sig Brokerage LP - MarketBeat

May 21, 2025
pulisher
May 21, 2025

ProShare Advisors LLC Boosts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

May 21, 2025
pulisher
May 21, 2025

Man Group plc Sells 24,377 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

May 21, 2025
pulisher
May 21, 2025

Sherbrooke Park Advisers LLC Purchases New Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

May 21, 2025
pulisher
May 21, 2025

Raiffeisen Bank International AG Invests $3.51 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

May 21, 2025
pulisher
May 21, 2025

Teza Capital Management LLC Acquires 429 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

May 21, 2025
pulisher
May 21, 2025

Soleus Capital Management L.P. Takes $1.64 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

May 21, 2025
pulisher
May 21, 2025

Victrix Investment Advisors Buys New Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

May 21, 2025
pulisher
May 21, 2025

Vestal Point Capital LP Invests $14.25 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

May 21, 2025
pulisher
May 21, 2025

Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal - AOL.com

May 21, 2025
pulisher
May 21, 2025

Triglav Skladi D.O.O. Invests $1.79 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

May 21, 2025
pulisher
May 21, 2025

Regeneron's 23andMe StealSmart Genetics Play That Won't Cure Near-Term Growth Pains - Seeking Alpha

May 21, 2025
pulisher
May 20, 2025

Mufg Securities Americas Inc. Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

May 20, 2025
pulisher
May 20, 2025

Regeneron Pharmaceuticals to Acquire 23andMe for $256M - MSN

May 20, 2025
pulisher
May 20, 2025

23andMe sold to Regeneron for $256M in court-supervised bankruptcy, sans Lemonaid. And is it worth it? - Telehealth and Telecare Aware

May 20, 2025
pulisher
May 20, 2025

Nuveen Asset Management LLC Sells 211,009 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

May 20, 2025
pulisher
May 20, 2025

Toronto Dominion Bank Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

May 20, 2025
pulisher
May 20, 2025

What Does Regeneron's Purchase of 23andMe Mean for Privacy? - Bank information security news

May 20, 2025

Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$75.06
price up icon 3.26%
$1.335
price up icon 6.39%
$4.25
price up icon 0.48%
$289.96
price up icon 0.33%
$587.61
price up icon 1.06%
Cap:     |  Volume (24h):